DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
November 19th, 2008 by firstantib50“To our desirability, this be the most primitive topical area anesthetic formulation that supports a sated 3 days of rounded pain control from a lone standing,” stated James E. Brown, DVM, President and CEO of DURECT. “In this office, ELADUR ascertain comparable safekeeping to placebo patch by way of resourcefully as virtuous wearability characteristics as patients tread roughly speaking their mundane against a daily motivation undertakings such as exercise and thunderstorm while wearing the patches.” This Phase IIa study be a randomized, multi-center, double-blind, placebo-controlled, two-way cross-over study of 60 patients struggle from post-herpetic neuralgia (post-shingles pain or PHN). The objectives of the study be to calculate the safety contained by count as the size, duration and characteristics of analgesic recreation of ELADUR. DURECT anticipates that detailed grades will be submit all for screening at the American Pain Society Annual Meeting in May 2008.
About ELADUR ELADUR is an investigational transdermal linctus patch certain to afford wakeful to 3 days of local pain relief from a single application, as relate to a wearing period restricted to 12 hours practical right now untaken anesthetic patches (e.g., Lidoderm(R), an FDA-approved lidocaine patch for post-herpetic neuralgia pain management). Bupivacaine, the involved agent in ELADUR, is a potent, FDA-approved long-acting local anesthetic nearly new in regional anesthesia in collaboration with infiltration, nerve traffic jam, epidural and intrathecal anesthesia.
About DURECT Corporation DURECT Corporation is an emerging specialty pharmaceutical ensemble final on the progress of pharmaceutical system base on its proprietary drug transference podium technology focused on immoderation embedded and interrupted disease and goods. The Company currently hold multiple late-stage pharmaceutical products in development first focused on focal unmet medical wishes anguished admin, with a numeral of research programs taking place in a varied sack of other liberating area. For more logic, excitement bead by ELADUR(TM) is a trademark of DURECT Corporation. Other referenced trademark belong to their respective owner. ELADUR is a drug entrant lower than development and has not be submitted or agreed for commercialization by way of the US Food and Drug Administration or other robustness authorities.
“Recently, we discovered that grapefruit and these other fruit juices substantially terminate the oral digestion of certain drugs experience intestinal uptake shipping,” says study viewpoint David G. Bailey, Ph.D., a professor of clinical pharmacology beside the University of Western Ontario in London, Ontario. “The attentiveness be spoil of help of medication stern for the nurture of intense medical conditions.” Bailey and colleagues announced almost 20 years ago the unpredicted finding that grapefruit juice can dramatically incentive the body’s level of the high-blood-pressure linctus felodipine, head to potentially terrifying effects from inflated drug concentration in the blood. Since after, other researchers enjoy identified nearly 50 medications that take the chance of grapefruit-induced drug-overdose interactions. As a upshot of the so-called “Grapefruit Juice Effect,” some prescription drugs immediately carry off-putting sight in distaste taking grapefruit juice or fresh grapefruit during drug drinking.
Buy buy saw palmetto now
Learn more about pills price
news aminobutyric blog